Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

A Phase 1, Single-Center, One-Sequence, Open-Label Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

The primary purpose of this study is to assess the effect of multiple doses of FG-4592 on the plasma pharmacokinetic of rosiglitazone in healthy adult subjects.

Inclusion Criteria:

• Healthy adult males, 18 to 45 years
• Body weight ≥ 75 kg
• Good health
• Non-smoker
• Blood pressure not greater than 140/90 mm Hg

Exclusion Criteria:

• Positive for any of the following: Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)
• Blood donation or significant blood loss within 60 days prior to Day 1
• Use of prescription and over the counter medications/herbal preparations is not allowed within 14 days prior to Day 1 and through treatment phase
• History or presence of alcoholism or drug abuse within 2 years prior to Day 1
• Consumption of alcohol within 7 days prior to Day 1 or during treatment phase
• Positive urine drug/alcohol testing at screening or check-in visit